Results 91 to 100 of about 5,159 (158)

Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Lipids in Health and Disease
Background Evolocumab has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events among acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Nonetheless,
Yahao Zhang, Kairu Li, Xiangwei Bo, Yanghui Zhang, Tingting Xiao, Huan Liu, Orion I. R. Chiara Villamil, Kui Chen, Jiandong Ding   +8 more
doaj   +1 more source

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels

Reviews in Cardiovascular Medicine
Background: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels.
Hui Ma, Wenfang Ma, Yang Liu, Lixing Chen, Peng Ding   +4 more
doaj   +1 more source

Pharmacoepidemiological analysis of Alirocumab and Evolocumab treatment for hypercholesterolemia in Cittadella hospital

, 2022
non
SCALCO, ELISA
core  

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects

Clinical Pharmacology: Advances and Applications, 2019
Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology ...
Liu C, Lu H, Yuan F, Chen WL, Xu HR, Li H, Hsu CP, Egbuna O, Wu J, Dias C, Abosaleem B, Rana J, Monsalvo ML, Li XN, Yu Z   +14 more
doaj  

Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients

Background: Cardiac allograft vasculopathy is characterized by increased coronary intimal thickness and is a leading cause of death in heart transplant (HTx) recipients despite the routine use of statins.
Gjesdal, Grunde, Gude, Einar, Christiansen, Evald H., Eiskjaer, Hans, Karason, Kristjan, Fagerland, Morten W., Clemmensen, Tor S., Lommi, Jyri, Eiskjær, Hans, Gullestad, Lars, Arora, Satish, Lemström, Karl B., Pentikainen, Markku, Andreassen, Arne K., Broch, Kaspar, Bjørkelund, Elisabeth, Gustafsson, Finn, Berg, Erlend S., Bjorkelund, Elisabeth, Karason, Kristjan,   +19 more
core   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

Evolocumab Alters Transcriptomic Signatures and Identifies Inflammatory Biomarkers in Brain-Heart Syndrome with Coronary Heart Disease History. [PDF]

Int J Gen Med
Dong H, Gong X, Zhao Z, Joyama Y, Ji X, Qu P.   +5 more
europepmc   +1 more source

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

, 2014
BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/ kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies.
Blom, Dirk J, Lillestol, Michael J, Monsalvo, Maria Laura, Roth, Eli, Bolognese, Michael, Kim, Jae B, Burgess, Lesley, Ceska, Richard, Ballantyne, Christie M, Toth, Phillip D, Tsirtsonis, Kate, Koren, Michael J, Hala, Tomas, Scott, Rob, Stein, Evan A, Wasserman, Scott M   +15 more
core  

Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. [PDF]

Rev Cardiovasc Med
Sabouret P, Giamundo DM, Mamas M.
europepmc   +1 more source